{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:32:16Z","timestamp":1783708336251,"version":"3.55.0"},"reference-count":121,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T00:00:00Z","timestamp":1241568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mount Sinai J Medicine"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinicians are faced with an expansive array of treatment choices when caring for patients with type 2 diabetes. Because patient compliance may be affected when media sensationalism about controversial findings is misunderstood, we sought to clarify the recent controversy surrounding the cardiovascular and bone\u2010health risks of thiazolidinediones, the risk of lactic acidosis with metformin, and the risk of hypoglycemia with oral therapies. The side effect profile of thiazolidinediones includes fluid retention, heart failure; and an increased risk of fracture. A recent controversial meta\u2010analysis suggested that rosiglitazone increases the risk of myocardial infarction, which is possibly related to thiazolidinedione\u2010induced lipid changes, weight gain, congestive heart failure, and anemia. Metformin is restricted to patients with normal renal function because of concerns that metformin may cause lactic acidosis. However, few cases of metformin\u2010associated lactic acidosis have been reported, and most have occurred in patients with other reasons for developing lactic acidosis, such as sepsis or renal failure. Although the use of metformin continues to increase, observational studies have not been able to demonstrate an increased incidence of lactic acidosis in metformin\u2010treated patients, even when it is used in populations with relative contraindications. Some oral hypoglycemic medications can cause hypoglycemia. Hypoglycemia is especially common in older patients, alcoholics, and patients with liver or renal disease. Patients on sulfonylureas and meglitinides have the highest incidence of hypoglycemia because of their pharmacological action of increasing insulin secretion. Of the sulfonylureas, glyburide presents the highest risk of hypoglycemia. Combination therapies, especially those regimens containing a sulfonylurea, increase the risk of hypoglycemia. Mt Sinai J Med 76:234\u2013243, 2009. \u00a9 2009 Mount Sinai School of Medicine<\/jats:p>","DOI":"10.1002\/msj.20116","type":"journal-article","created":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T15:14:25Z","timestamp":1241622865000},"page":"234-243","source":"Crossref","is-referenced-by-count":31,"title":["Balancing Risk and Benefit with Oral Hypoglycemic Drugs"],"prefix":"10.1002","volume":"76","author":[{"given":"Ole\u2010Petter R.","family":"Hamnvik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham T.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"US Food and Drug Administration. Approvals for January 1997. Available at:http:\/\/www.fda.gov\/cder\/da\/da0197.htm. Accessed April 2009."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566524053766068"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041001"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.11.1605"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.1.7157"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0074-6"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.2983"},{"key":"e_1_2_1_9_2","unstructured":"US Food and Drug Administration. MedWatch August 2007. Safety\u2010related drug labeling changes\u2014detailed. Available at:http:\/\/www.fda.gov\/medwatch\/safety\/2007\/aug07.htm. Accessed April 2009."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.3132\/dvdr.2007.022"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe078099"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc071602"},{"key":"e_1_2_1_14_2","unstructured":"GlaxoSmithKline. Study no. ZM2005\/00181\/01: Avandia cardiovascular event modeling project. Available at:http:\/\/www.gsk\u2010clinicalstudyregister.com\/files\/pdf\/24040.pdf. Accessed April 2009."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073394"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe078116"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60824-1"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp078167"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.20.joc50147"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1470"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000025403.20953.23"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi113"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.03.039"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.11.2654"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.55.03.06.db05-0832"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.13.1561"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.3132\/dvdr.2007.023"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007740300026"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.9.2915"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116622"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200419900"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-0746"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.46.795"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2226"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2606"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2646"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2270"},{"key":"e_1_2_1_41_2","unstructured":"Takeda Pharmaceuticals North America Inc. Re: Observation of an increased incidence of fractures in female patients who received long\u2010term treatment with ACTOS\u00ae(pioglitazone HCl) tablets for type 2 diabetes mellitus. Available at:http:\/\/www.fda.gov\/medwatch\/safety\/2007\/actosmar0807.pdf.Accessed April 2009."},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.8.820"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe078117"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.02.024"},{"key":"e_1_2_1_45_2","first-page":"523","article-title":"Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk\u2010warning events","volume":"14","author":"Starner CI","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602293340906"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-1-200207020-00009"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508313330902"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1963.03700140093013"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-5-591"},{"key":"e_1_2_1_51_2","unstructured":"US Food and Drug Administration. Why drugs get pulled off the market. Available at:http:\/\/www.fda.gov\/fdac\/features\/2002\/102_drug.html. Accessed April 2009."},{"key":"e_1_2_1_52_2","unstructured":"US Food and Drug Administration. Orange book detail record search. Available at:http:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/docs\/obdetail.cfm?appl_no=020357&table1=ob_rx. Accessed April 2009."},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.15.6.755"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3002(58)90058-1"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj3480607"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb09093.x"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.46.9.1406"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0953-6205(02)00131-0"},{"key":"e_1_2_1_59_2","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","author":"Salpeter S","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C183"},{"key":"e_1_2_1_61_2","first-page":"45","article-title":"The hyperlactatemic effect of biguanides: a comparison between phenformin and metformin during a 6\u2010month treatment","volume":"11","author":"Cavallo\u2010Perin P","year":"1989","journal-title":"Riv Eur Sci Med Farmacol"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801223380415"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pap.0000249953.92311.23"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1017\/S026502150700097X"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.4103\/0971-9784.37927"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP66380"},{"key":"e_1_2_1_67_2","first-page":"1923","article-title":"Severe lactic acidosis due to metformin therapy in a patient with contra\u2010indications for metformin [in Dutch]","volume":"144","author":"Houwerzijl EJ","year":"2000","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg049"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn152"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.6.925"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.045292"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01271.x"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.6.779"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2007.11.055"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.11.2036"},{"issue":"4","key":"e_1_2_1_76_2","first-page":"126","article-title":"Metformin\u2010associated lactic acidosis in diabetic patients with acute renal failure. A critical analysis of its pathogenesis and prognosis","volume":"9","author":"Lalau JD","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-1-126"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.6.925"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02440866"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.10.1659"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2001.00509.x"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.4.434"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.19.2504-a"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000154542.13412.B1"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806359"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-9912"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0026-1"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn156"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-008-9371-6"},{"key":"e_1_2_1_91_2","first-page":"297","article-title":"Metformin lactic acidosis and anaesthesia: myth or reality?","volume":"56","author":"Vreven R","year":"2005","journal-title":"Acta Anaesthesiol Belg"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-6-200709180-00178"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.9.1495"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00839.x"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17360"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979831"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.235"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1996.tb03729.x"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.2.142"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199631020-00003"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440360095010"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30395-5"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00024-3"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550010054039"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.3.307"},{"key":"e_1_2_1_106_2","first-page":"393","article-title":"Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care","volume":"53","author":"Goudswaard AN","year":"2004","journal-title":"J Fam Pract"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C492"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2005.10.024"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-5-199903020-00002"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1031414"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2008.tb01713.x"},{"key":"e_1_2_1_112_2","first-page":"185","article-title":"Reality of severe metformin\u2010induced lactic acidosis in the absence of chronic renal impairment","volume":"66","author":"Bruijstens LA","year":"2008","journal-title":"Neth J Med"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1136\/emj.2007.054213"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00657.x"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2007.09.034"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/ael347"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1159\/000132463"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650701355314"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1556-4029.2007.00461.x"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1097\/BCR.0B013E318031A1FE"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.smj.0000240718.26385.69"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200825070-00006"}],"container-title":["Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsj.20116","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsj.20116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/msj.20116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T22:49:03Z","timestamp":1699915743000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/msj.20116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,6]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1002\/msj.20116"],"URL":"https:\/\/doi.org\/10.1002\/msj.20116","archive":["Portico"],"relation":{},"ISSN":["0027-2507","1931-7581"],"issn-type":[{"value":"0027-2507","type":"print"},{"value":"1931-7581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,6]]}}}